13D Filing: Biotime Inc and Asterias Biotherapeutics Inc.

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
D.C. 20549

 

 

SCHEDULE
13D

 

Under
the Securities Exchange Act of 1934

 

(Amendment
No. 5)

 

ASTERIAS
BIOTHERAPEUTICS, INC.

(Name
of Issuer)

 

Series A Common Stock, par value $0.0001 per share		04624N 107
(Title of class of securities)		(CUSIP number)

 

Russell
Skibsted

Chief
Financial Officer

BioTime,
Inc.

1010
Atlantic Avenue

Suite
102

Alameda,
California 94501

(510)
521-3390

(Name,
address and telephone number of person authorized to receive notices and communications)

 

March
28, 2017

(Date
of event which requires filing of this statement)

 

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [  ].

 

Note:
When filing this statement in paper format, six copies of this statement, including exhibits, should be filed with the Commission.
See Rule 13d-1(a) for other parties to whom copies are to be sent.

 

(Continued
on following page(s))